OSE Immunotherapeutics (ENXTPA:OSE) - Share price, News & Analysis

OSE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

OSE Stock Overview

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.

Rewards

Trading at 99.3% below our estimate of its fair value

Revenue is forecast to grow 38.81% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

OSE Immunotherapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OSE Immunotherapeutics
Historical stock prices
Current Share Price	€6.93
52 Week High	€13.68
52 Week Low	€4.60
Beta	0.90
1 Month Change	3.13%
3 Month Change	0.73%
1 Year Change	-38.24%
3 Year Change	93.58%
5 Year Change	2.67%
Change since IPO	-33.68%

Recent News & Updates

May 11

OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be

The latest analyst coverage could presage a bad day for OSE Immunotherapeutics SA ( EPA:OSE ), with the analysts making...

Shareholder Returns

	OSE	FR Biotechs	FR Market
7D	1.3%	-0.4%	3.7%
1Y	-38.2%	-39.4%	-3.7%

Return vs Industry: OSE exceeded the French Biotechs industry which returned -39.4% over the past year.

Return vs Market: OSE underperformed the French Market which returned -3.7% over the past year.

Price Volatility

Is OSE's price volatile compared to industry and market?
OSE volatility
OSE Average Weekly Movement	14.2%
Biotechs Industry Average Movement	8.8%
Market Average Movement	5.9%
10% most volatile stocks in FR Market	10.0%
10% least volatile stocks in FR Market	3.4%

Stable Share Price: OSE is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: OSE's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
n/a	53	Dominique Costantini	https://www.ose-immuno.com

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company’s products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation.

OSE Immunotherapeutics Fundamentals Summary

How do OSE Immunotherapeutics's earnings and revenue compare to its market cap?
OSE fundamental statistics
Market Cap	€128.22m
Earnings (TTM)	-€16.85m
Revenue (TTM)	€26.31m

4.9x

P/S Ratio

-7.6x

P/E Ratio

Is OSE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
OSE income statement (TTM)
Revenue	€26.31m
Cost of Revenue	€0
Gross Profit	€26.31m
Other Expenses	€43.16m
Earnings	-€16.85m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.91
Gross Margin	100.00%
Net Profit Margin	-64.05%
Debt/Equity Ratio	67.7%

How did OSE perform over the long term?

See historical performance and comparison

Valuation

Is OSE Immunotherapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: OSE (€6.93) is trading below our estimate of fair value (€945.04)

Significantly Below Fair Value: OSE is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: OSE is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: OSE is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSE's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: OSE's Price-To-Book Ratio (2.7x) is in line with the FR Biotechs industry average.

Future Growth

How is OSE Immunotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

36.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OSE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OSE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OSE's revenue (38.8% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: OSE's revenue (38.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OSE's Return on Equity is forecast to be high in 3 years time

Past Performance

How has OSE Immunotherapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-50.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OSE is currently unprofitable.

Growing Profit Margin: OSE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: OSE is unprofitable, and losses have increased over the past 5 years at a rate of 50.6% per year.

Accelerating Growth: Unable to compare OSE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: OSE has a negative Return on Equity (-35.18%), as it is currently unprofitable.

Financial Health

How is OSE Immunotherapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OSE's short term assets (€44.2M) exceed its short term liabilities (€16.8M).

Long Term Liabilities: OSE's short term assets (€44.2M) exceed its long term liabilities (€37.2M).

Debt to Equity History and Analysis

Debt Level: OSE has more cash than its total debt.

Reducing Debt: OSE's debt to equity ratio has increased from 2.8% to 67.7% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OSE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OSE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is OSE Immunotherapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OSE has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure

CEO

Dominique Costantini (65 yo)

10.33yrs

Tenure

€411,775

Compensation

Dr. Dominique Costantini, M.D. serves as Interim Chief Executive Officer at OSE Immunotherapeutics SA since January 17, 2022. She Co-founded OSE Pharma SA in 2012 and serves as its Chief Executive Officer....

CEO Compensation Analysis

Compensation vs Market: Dominique's total compensation ($USD441.16K) is above average for companies of similar size in the French market ($USD285.89K).

Compensation vs Earnings: Dominique's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: OSE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Experienced Board: OSE's board of directors are considered experienced (8.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/28 00:00
End of Day Share Price	2022/05/27 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31